Mineralys Therapeutics announced on June 30, 2025, the publication of positive results from its pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association (JAMA). The manuscript, titled 'Lorundrostat in Participants with Uncontrolled and Treatment-Resistant Hypertension,' was featured in the June 30, 2025, issue.
The Launch-HTN trial, the largest of an aldosterone synthase inhibitor to date, enrolled 1,083 participants and demonstrated that lorundrostat 50 mg once daily significantly reduced systolic blood pressure. A 16.9 mmHg reduction was observed at Week 6 (-9.1 mmHg placebo adjusted; p < 0.0001), sustained with a 19.0 mmHg reduction at Week 12 (-11.7 mmHg placebo adjusted; p < 0.0001).
The publication in JAMA, a prestigious medical journal, provides strong scientific validation for lorundrostat's efficacy and favorable safety and tolerability profile. This reinforces the drug's potential as a best-in-class treatment for patients with uncontrolled or treatment-resistant hypertension, addressing a key driver of the condition.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.